JP2021501208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501208A5 JP2021501208A5 JP2020543443A JP2020543443A JP2021501208A5 JP 2021501208 A5 JP2021501208 A5 JP 2021501208A5 JP 2020543443 A JP2020543443 A JP 2020543443A JP 2020543443 A JP2020543443 A JP 2020543443A JP 2021501208 A5 JP2021501208 A5 JP 2021501208A5
- Authority
- JP
- Japan
- Prior art keywords
- imino
- ethoxy
- isopropylidene
- india
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 chloro, iodo Chemical group 0.000 claims 67
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims 63
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000005999 2-bromoethyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004492 methyl ester group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- CWLGSMSIROEVBR-UHFFFAOYSA-N CC(C)CCNC1CCNCC1 Chemical compound CC(C)CCNC1CCNCC1 CWLGSMSIROEVBR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170144142 | 2017-10-31 | ||
| KR10-2017-0144142 | 2017-10-31 | ||
| PCT/KR2018/013051 WO2019088677A1 (ko) | 2017-10-31 | 2018-10-30 | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501208A JP2021501208A (ja) | 2021-01-14 |
| JP2021501208A5 true JP2021501208A5 (enExample) | 2021-02-25 |
| JP7005779B2 JP7005779B2 (ja) | 2022-02-10 |
Family
ID=66333236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543443A Active JP7005779B2 (ja) | 2017-10-31 | 2018-10-30 | 急性骨髄性白血病又は転移性乳癌の予防又は治療用薬剤学的組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11370779B2 (enExample) |
| EP (1) | EP3705474A4 (enExample) |
| JP (1) | JP7005779B2 (enExample) |
| KR (1) | KR102247795B1 (enExample) |
| CN (1) | CN111542513A (enExample) |
| AU (1) | AU2018358582B2 (enExample) |
| BR (1) | BR112020008499A2 (enExample) |
| CA (1) | CA3080900C (enExample) |
| MX (1) | MX2020004374A (enExample) |
| PH (1) | PH12020550491A1 (enExample) |
| RU (1) | RU2763346C2 (enExample) |
| WO (1) | WO2019088677A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021552551A1 (en) | 2019-04-26 | 2022-06-20 | Unilever Ip Holdings B V | Hair conditioning composition |
| CN110305056A (zh) * | 2019-05-22 | 2019-10-08 | 西北大学 | 靛玉红新衍生物及其药用用途 |
| WO2021090172A1 (en) * | 2019-11-04 | 2021-05-14 | Ck Biotechnology Co. | Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof |
| KR102296440B1 (ko) * | 2019-12-06 | 2021-09-02 | 주식회사 펠레메드 | 신규한 인디루빈 유도체 및 이의 용도 |
| KR102443617B1 (ko) * | 2019-12-06 | 2022-09-16 | 광주과학기술원 | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 |
| KR102325607B1 (ko) | 2020-02-20 | 2021-11-12 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| KR20210106155A (ko) | 2020-02-20 | 2021-08-30 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| KR102278176B1 (ko) | 2020-02-20 | 2021-07-16 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
| KR102744517B1 (ko) * | 2022-02-14 | 2024-12-19 | 주식회사 펠레메드 | 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도 |
| EP4674839A1 (en) * | 2023-02-28 | 2026-01-07 | CK Regeon Inc. | Novel indoline derivative and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200101046A1 (ru) * | 1999-04-12 | 2002-04-25 | Герхард Айзенбранд | Производные индигоидных бис-индолов |
| FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| JP5448455B2 (ja) | 2005-12-23 | 2014-03-19 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク （セ エン エール エス） | 新規３’−，７−置換インジルビンおよびそれらの適用 |
| EP2149553B1 (en) | 2008-08-01 | 2011-10-19 | Centre National de la Recherche Scientifique | 3', 6-substituted indirubins and their biological applications |
| KR101180030B1 (ko) * | 2010-02-05 | 2012-09-05 | 광주과학기술원 | 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체 |
| EP2518139A1 (en) * | 2011-04-27 | 2012-10-31 | Universitätsklinikum Jena | Use of indirubin derivatives for producing pluripotent stem cells |
| US10435367B2 (en) * | 2013-03-14 | 2019-10-08 | City Of Hope | Indirubin derivatives, and uses thereof |
| WO2013142817A2 (en) * | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| AU2014236370C1 (en) * | 2013-03-14 | 2019-01-17 | City Of Hope | 5-bromo-indirubins |
| US20150259288A1 (en) * | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
-
2018
- 2018-10-30 KR KR1020180131294A patent/KR102247795B1/ko active Active
- 2018-10-30 CA CA3080900A patent/CA3080900C/en active Active
- 2018-10-30 EP EP18873750.6A patent/EP3705474A4/en active Pending
- 2018-10-30 JP JP2020543443A patent/JP7005779B2/ja active Active
- 2018-10-30 RU RU2020115581A patent/RU2763346C2/ru active
- 2018-10-30 AU AU2018358582A patent/AU2018358582B2/en active Active
- 2018-10-30 WO PCT/KR2018/013051 patent/WO2019088677A1/ko not_active Ceased
- 2018-10-30 BR BR112020008499-9A patent/BR112020008499A2/pt not_active IP Right Cessation
- 2018-10-30 CN CN201880084849.8A patent/CN111542513A/zh active Pending
- 2018-10-30 MX MX2020004374A patent/MX2020004374A/es unknown
-
2020
- 2020-04-24 PH PH12020550491A patent/PH12020550491A1/en unknown
- 2020-04-30 US US16/862,923 patent/US11370779B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020115581A (ru) | Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы | |
| JP6511430B2 (ja) | がんの治療のための化合物および組成物 | |
| JP2009541223A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| ES2576497T3 (es) | Compuesto de piperidina novedoso o sal del mismo | |
| JP2018529739A5 (enExample) | ||
| JP2016520618A5 (enExample) | ||
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| JP2019524883A5 (enExample) | ||
| JP2019512535A5 (enExample) | ||
| JP2010528021A5 (enExample) | ||
| JP2007528379A5 (enExample) | ||
| JP2008528468A5 (enExample) | ||
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2016540742A5 (enExample) | ||
| RU2004121161A (ru) | Замещенные 2-тио-3,5-дициано-4-фенил-6-аминопиридины и их применение | |
| JP2010526098A5 (enExample) | ||
| JP2008500997A5 (enExample) | ||
| NO20081582L (no) | Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer | |
| RU2006108799A (ru) | N3-замещенные имидазопиридиновые ингибиторы c-kit | |
| MX2016014574A (es) | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. | |
| Yadav et al. | Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo [d] imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides | |
| JP2015504091A5 (enExample) | ||
| JPWO2012144463A1 (ja) | 腫瘍治療剤 | |
| JP2019535709A5 (enExample) |